Antigen specific active immunotherapy: Lessons from the first decade

Swiss Medical Weekly

Volumn 135, Issue 15-16, 2005, Pages 212-221

  Adamina, Michel ^a   Oertli, Daniel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Immunotherapy; Melanoma; Recombinant virus; Tumour associated antigen

Indexed keywords

ALPHA INTERFERON; ALUMINUM POTASSIUM SULFATE; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CD86 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; EPITOPE; FREUND ADJUVANT; GANGLIOSIDE; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A0201 ANTIGEN; HLA ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; LIPOSOME; MELACINE; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; QS 21; SYNTHETIC PEPTIDE; TRIGEM; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE;

ACTIVE IMMUNIZATION; ANTIGEN SPECIFIC ACTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CELL LYSATE; CLINICAL TRIAL; DRUG MEGADOSE; GENE GUN; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MEDICAL TECHNOLOGY; MELANOMA; MELANOMA ASSOCIATED RETINOPATHY; RETINOPATHY; SHORT SURVEY; SWITZERLAND; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR ESCAPE; UVEITIS; VIRUS RECOMBINANT; VISUAL FIELD DEFECT; VITILIGO;

EID: 18744385853     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (63)

1. Woodruff MF, Nolan B. Preliminary observations on treatment of advanced cancer by injection of allogeneic spleen cells. Lancet 1963;13:426-9.
2. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
3. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
4. Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumour-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002;236:785-93.
5. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. Acontrolled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
6. Jenner E in Sampson Low (Soho, London 1798).
7. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumour escape. Nat Immunol 2002;3:991-8.
8. Zinkernagel RM. On differences between immunity and immunological memory. Curr Opin Immunol 2002;14:523-36.
9. Wodarz D. Hepatitis C virus dynamics and pathology: the role of CTL and antibody responses. J Gen Virol 2003;84:1743-50.
10. O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003; 2:727-35.
11. Schumacher R, Adamina M, Zurbriggen R, Bolli M, Padovan E, Zajac P, et al. Influenza virosomes enhance class I restricted CTL induction through CD4 T cell activation. Vaccine 2004; 22:714-23.
12. Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 1998;25: 611-22.
13. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25:623-35.
14. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicentre vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187: 69-77.
15. Ritter G, Livingston PO. Ganglioside antigens expressed by human cancer cells. Semin Cancer Biol 1991;2:401-9.
16. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
17. Celis, E. Getting peptide vaccines to work: just a matter of quality control? J Clin Invest 2002;110:1765-8.
18. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincok FM, et al. Cancer immunotherapy with peptide based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805-18.
19. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
20. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67:54-62.
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
22. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003;21:2342-8.
23. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, et al. Granulocyte-macrophage colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003;97:186-200.
24. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high risk melanoma. Clin Cancer Res 1999;5:2756-65.
25. + melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 2002;8:967-72.
26. Amoscato AA, Prenowitz DA, Lotze MT. Rapid extacellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 1998;161:4023-32.
27. Albo F, Cavazza A, Giardina B, Marini M, Roda LG, Schumacher R, et al. Degradation of the tumor antigen epitope gp100 (280-288) by fibroblast- associated enzymes abolishes specific immunorecognition. Biochim Biophys Acta 2004;167: 59-69.
28. Blanchet JS, Valmori D, Dufau I, Ayyoub M, Nguyen C, Guillaume P, et al. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implications for molecular anti-melanoma immunotherapy. J Immunol 2001;167:5852-61.
29. + T-cell responses. J Clin Oncol 2003;21:1562-73.
30. Adamina M, Bolli M, Albo F, Cavazza A, Zajac P, Padovan E, et al. Encapsulation into sterically stabilized liposomes improves the immunogenicity of melanoma associated Mart-1/Melan-A epitope. Br J Cancer 2004;90:263-9.
31. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10: 475-80.
32. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
33. +) hematopoietic progenitor cells. Int J Cancer 2000;86:385-92.
34. +) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
35. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
36. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev T, et al. Vaccination with hybrids of tumour and dendritic cells induces tumour-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 2004;110: 730-40.
37. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunological results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
38. Bedrosian I, Mick R, Xu S, Nisenbaum H, Paries M, Zhang P, et al. Intranodal administration of peptide-pulsed nature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003;21:3826-35.
39. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90: 1894-900.
40. Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, Padovan E, et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum Gene Ther 2002;13: 569-75.
41. Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Culler U, et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003;14:1497-510.
42. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunization by parenteral, mucosal and gene-gun inoculations. Roc Natl Acad Sci USA 2003;90:11478-82.
43. Kurth R. Risk potential of the chromosomal insertion of foreign DNA. Ann NY Acad Sci 1995;772:140-51.
44. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003;14: 709-14.
45. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 2003;98: 144-54.
46. Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;1: 577-80.
47. + cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-73.
48. Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 2003;170:2161-9.
49. + T cells. J Exp Med 2002;195:1515-22.
50. + cells. J Exp Med 2002;195:1523-32.
51. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
52. Cassone A, Mastrantonio P, Ausiello CM. Are only antibody levels involved in the protection against pertussis in acellular pertussis vaccine recipients? J Infect Dis 2000;186:351-60.
53. Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 2004;53:249-55.
54. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
55. Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, et al. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001;166:7634-40.
56. Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde KH, Wolfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 1997;203:141-52.
57. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999;163:6867-75.
58. + T cells in subjects bearing either HLA-A 2402 or A 0101 allele. Transfusion 2004;43:1567-74.
59. Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, et al. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol 2000;164: 495-504.
60. Sosman JA, Weeraratna AT, Sondak VK, When will melanoma vaccines be proven effective? J Clin Oncol 2004;22:387-89.
61. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74: 181-273.
62. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nature Rev Immunol 2003;3: 269-79.
63. Zinkernagel RM. Immunity against solid tumors? Int J Cancer 2001;93:1-5.